PMID- 36951078
OWN - NLM
STAT- MEDLINE
DCOM- 20230324
LR  - 20230324
IS  - 1000-0607 (Print)
IS  - 1000-0607 (Linking)
VI  - 48
IP  - 3
DP  - 2023 Mar 25
TI  - [Effect of penetrative needling of "Zhibian" (BL54) through "Shuidao" (ST28) on 
      expression of TRAIL and its receptors in rats with premature ovarian 
      insufficiency].
PG  - 259-66
LID - 10.13702/j.1000-0607.20220251 [doi]
AB  - OBJECTIVE: To observe the effect of penetrative needling of "Zhibian" (BL54) 
      through "Shuidao" (ST28) on the expressions of death receptor pathway-related 
      protein tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its 
      receptors, as death receptor 4 (DR4), death receptor 5 (DR5), decoy receptor 1 
      (DcR1) and decoy receptor 2 (DcR2) in premature ovarian insufficiency (POI) rats, 
      so as to explore its mechanisms underlying improvement of POI. METHODS: Forty 
      female SD rats were randomly divided into blank control, model, penetrative 
      needling and medication (estradiol valerate) groups, with 10 rats in each group. 
      The POI model was established by intraperitoneal injection of cyclophosphamide 
      (D1: 50 mg.kg(-1).d(-1), D2 to D15: 8 mg.kg(-1).d(-1), for a total of 15 d). 
      After successful modeling, the rats in the penetrative needling group received 
      penetrative needling of BL54 through ST28, with the needle retained for 30 min, 
      once a day for a total of 4 weeks. Rats of the medication group received gavage 
      of estradiol valerate (0.09 mg.kg(-1).d(-1)) once daily for 4 weeks. After the 
      intervention, the content of serum follicles of stimulation hormone 
      (FSH),lateinizing hormone (LH),estradiol (E2) and vascular endothelial growth 
      factor (VEGF) were assayed using enzyme-linked immunosorbent assay, and 
      histopathological changes of ovarian tissue and the number of follicles were 
      observed under light microscope after H.E. staining. The expression levels of 
      TRAIL, DR4, DR5, DcR1, DcR2, and Fas-associated death domain (FADD) in ovarian 
      tissues were detected using quantitative real-time PCR, and the immunoactivity of 
      ovarian TRAIL, DR4 and DR5 detected using immunohistochemistry. The body weight 
      and the damp weight of ovary were measured for calculating the ovarian 
      coefficient. RESULTS: Compared with the blank control group, the E2 and VEGF 
      contents, ovarian coefficient, and the number of the primary, secondary and sinus 
      follicles were significantly decreased (P<0.01) in the model group, whereas FSH 
      and LH contents, the atretic follicle number, TRAIL, DR4 and DR5 immunoactivity, 
      and the expression levels of TRAIL, DR4, DR5 and FADD mRNAs considerably 
      increased in the model group (P<0.01). In comparison with the model group, the 
      decrease of the VEGF content, ovarian coefficient, and the number of the primary, 
      secondary and sinus follicles, and the increase of the atretic follicle number, 
      TRAIL, DR4 and DR5 immunoactivity, and expression levels of TRAIL, DR4, DR5 and 
      FADD mRNAs were reversed in both penetrative needling and medication groups 
      (P<0.01, P<0.05). The number of primary follicles was significantly more in the 
      medication group than in the penetrative needling group (P<0.01). CONCLUSION: 
      Penetrative needling of BL54 and ST28 can improve ovarian weight and promote 
      follicular development in POI rats, which may be associated with its function in 
      down-regulating the expression of pro-apoptotic proteins TRAIL, DR4, DR5 and FADD 
      of the death receptor pathway to inhibit apoptosis of ovarian granulosa cells.
FAU - Jin, Xiao-Fei
AU  - Jin XF
AD  - The Second Clinical College of Shanxi University of Chinese Medicine, Jinzhong 
      030619, Shanxi Province, China.
FAU - Yan, Jing
AU  - Yan J
AD  - The Second Clinical College of Shanxi University of Chinese Medicine, Jinzhong 
      030619, Shanxi Province, China.
FAU - Zhao, Ji-Yu
AU  - Zhao JY
AD  - The Second Clinical College of Shanxi University of Chinese Medicine, Jinzhong 
      030619, Shanxi Province, China.
FAU - Yin, Lu-Yun
AU  - Yin LY
AD  - The Second Clinical College of Shanxi University of Chinese Medicine, Jinzhong 
      030619, Shanxi Province, China.
FAU - Ma, Meng-Na
AU  - Ma MN
AD  - The Second Clinical College of Shanxi University of Chinese Medicine, Jinzhong 
      030619, Shanxi Province, China.
FAU - Wang, Hong-Yang
AU  - Wang HY
AD  - The Second Clinical College of Shanxi University of Chinese Medicine, Jinzhong 
      030619, Shanxi Province, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhen Ci Yan Jiu
JT  - Zhen ci yan jiu = Acupuncture research
JID - 8507710
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Ligands)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4TI98Z838E (Estradiol)
RN  - 0 (Receptors, Death Domain)
RN  - 9002-68-0 (Follicle Stimulating Hormone)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Female
MH  - Animals
MH  - *Vascular Endothelial Growth Factor A/genetics
MH  - Rats, Sprague-Dawley
MH  - Ligands
MH  - Apoptosis
MH  - *Primary Ovarian Insufficiency/genetics/therapy
MH  - Tumor Necrosis Factor-alpha
MH  - Estradiol
MH  - Receptors, Death Domain
MH  - Follicle Stimulating Hormone
OTO - NOTNLM
OT  - Death receptors
OT  - Penetrative acupuncture
OT  - Premature ovarian insufficiency
OT  - TRAIL
OT  - Zhibian(BL54) through Shuidao (ST28)
EDAT- 2023/03/24 06:00
MHDA- 2023/03/25 06:00
CRDT- 2023/03/23 05:03
PHST- 2023/03/23 05:03 [entrez]
PHST- 2023/03/24 06:00 [pubmed]
PHST- 2023/03/25 06:00 [medline]
AID - 10.13702/j.1000-0607.20220251 [doi]
PST - ppublish
SO  - Zhen Ci Yan Jiu. 2023 Mar 25;48(3):259-66. doi: 10.13702/j.1000-0607.20220251.